INTRODUCTION: Radiation resistance is a major cause of death in cancer patients. Cancer cells react during radiotherapy by re-programming specific cell functions that may confer resistance to radiation. The understanding of this complex process is hindered due to the lack of appropriate study models. We describe an experimental development of a radioresistant isogenic cancer cell line, and its molecular characterization. MATERIALS AND METHODS: A431-cultured cells were irradiated for 7 month until 85 Gy. Then, a selected single cell was left to grow as stable A431-R cell line. Clonogenic assay was used to determine cell survival, the α and β parameters of the LQ model, and the mean inactivation dose. The DNA repair ability of cells was evaluated by pulsed-field electrophoresis method. Differential effect of fractionated radiation was ultimately tested in xenografts. Furthermore, we used a wound healing assay, Western blot for EGFR, AKT and ERK1/2 and ELISA test for vascular endothelial growth factor (VEGF) secretion. Finally we explored CD44 marker and cell cycle distribution. RESULTS: The established A431-R cell line showed radiation resistance in clonogenic assays, repair of radiation-induced DNA fragmentation and xenografted tumours. The radiation resistance was associated with in vitro higher cell growth and migration, increased levels of former oncoproteins, and secretion of VEGF. CONCLUSIONS: In this model, the emergence of radiation resistance was associated with the acquisition of biological traits that support more aggressive behaviour of cancer cells. We have generated a model that will be useful for mechanistic studies and development of rational treatments against radiation resistance in cancer.
INTRODUCTION: Radiation resistance is a major cause of death in cancerpatients. Cancer cells react during radiotherapy by re-programming specific cell functions that may confer resistance to radiation. The understanding of this complex process is hindered due to the lack of appropriate study models. We describe an experimental development of a radioresistant isogenic cancer cell line, and its molecular characterization. MATERIALS AND METHODS: A431-cultured cells were irradiated for 7 month until 85 Gy. Then, a selected single cell was left to grow as stable A431-R cell line. Clonogenic assay was used to determine cell survival, the α and β parameters of the LQ model, and the mean inactivation dose. The DNA repair ability of cells was evaluated by pulsed-field electrophoresis method. Differential effect of fractionated radiation was ultimately tested in xenografts. Furthermore, we used a wound healing assay, Western blot for EGFR, AKT and ERK1/2 and ELISA test for vascular endothelial growth factor (VEGF) secretion. Finally we explored CD44 marker and cell cycle distribution. RESULTS: The established A431-R cell line showed radiation resistance in clonogenic assays, repair of radiation-induced DNA fragmentation and xenografted tumours. The radiation resistance was associated with in vitro higher cell growth and migration, increased levels of former oncoproteins, and secretion of VEGF. CONCLUSIONS: In this model, the emergence of radiation resistance was associated with the acquisition of biological traits that support more aggressive behaviour of cancer cells. We have generated a model that will be useful for mechanistic studies and development of rational treatments against radiation resistance in cancer.
Authors: Niamh Lynam-Lennon; John V Reynolds; Graham P Pidgeon; Joanne Lysaght; Laure Marignol; Stephen G Maher Journal: Radiat Res Date: 2010-10-04 Impact factor: 2.841
Authors: Mahmoud Toulany; Tim-Andre Schickfluss; Kazi R Fattah; Kyung-Jong Lee; Benjamin P C Chen; Birgit Fehrenbacher; Martin Schaller; David J Chen; H Peter Rodemann Journal: Radiother Oncol Date: 2011-06-30 Impact factor: 6.280
Authors: Klaus Dittmann; Claus Mayer; Birgit Fehrenbacher; Martin Schaller; Uma Raju; Luka Milas; David J Chen; Rainer Kehlbach; H Peter Rodemann Journal: J Biol Chem Date: 2005-07-05 Impact factor: 5.157
Authors: Monique C de Jong; Jimmy Pramana; Jacqueline E van der Wal; Martin Lacko; Carine J Peutz-Kootstra; Jos M de Jong; Robert P Takes; Johannes H Kaanders; Bernard F van der Laan; Jasper Wachters; Jeroen C Jansen; Coen R Rasch; Marie-Louise F van Velthuysen; Reidar Grénman; Frank J Hoebers; Ed Schuuring; Michiel W van den Brekel; Adrian C Begg Journal: Clin Cancer Res Date: 2010-09-13 Impact factor: 12.531
Authors: K Fukuda; C Sakakura; K Miyagawa; Y Kuriu; S Kin; Y Nakase; A Hagiwara; S Mitsufuji; Y Okazaki; Y Hayashizaki; H Yamagishi Journal: Br J Cancer Date: 2004-10-18 Impact factor: 7.640
Authors: N McDermott; A Meunier; B Mooney; G Nortey; C Hernandez; S Hurley; N Lynam-Lennon; S H Barsoom; K J Bowman; B Marples; G D D Jones; L Marignol Journal: Sci Rep Date: 2016-10-05 Impact factor: 4.379